Login to Your Account

ITS' Flunisyn Elicits Strong T-Cell Response in Phase IIa

By Nuala Moran
Staff Writer

Tuesday, April 16, 2013
LONDON – Immune Targeting Systems Ltd. (ITS) presented positive data on its universal influenza vaccine, Flunisyn, showing that it induced T-cell responses in 95 percent of subjects in an elderly population, ages 65 to 74, in a Phase IIa trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription